Clinical trials: Intravenous Infusions
Healthy Volunteers
A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers
This study will compare the pharmacodynamics, pharmacokinetics and safety of efgartigimod as an intravenous infusion with efgartigimod as a subcutaneous injection in healthy adults.
- Trial name
- NCT04564066
- Testing
- efgartigimod IV, efgartigimod PH20 SC
- Where
- Netherlands
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- argenx
Healthy
Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male Subjects
To investigate safety, tolerability, and pharmacokinetics (PK) of single i.v. doses of BI 1744 CL
- Trial name
- NCT02172131
- Testing
- BI 1744 CL
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Drug Kinetics, Drug Effects on Physiology
Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, Intravenously, or by Inhalation
This single center, single ascending dose (SAD) and repeat dose study in healthy adults comprises 2 parts. Part 1 will consist of 6 SAD cohorts, in which different dose levels of sargramostim will be given by intravenous (IV)…
- Trial name
- NCT05366283
- Testing
- sargramostim
- Where
- Canada
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Partner Therapeutics, Inc.
Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers
Study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 1356 as formulation for intravenous administration
- Trial name
- NCT02183298
- Testing
- BI 1356 BS - intravenous, BI 1356 BS - Tablet
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study
The purpose of this study will be to evaluate the safety and tolerability of lecanemab at sequentially ascending doses in subjects with mild to moderate Alzheimer's disease (AD).
- Trial name
- NCT01230853
- Testing
- Active Comparator: A, Active Comparator B
- Where
- 8 sites in United States
- Volunteers
- 80 people
- Sponsor
- Eisai Inc.
Healthy
Single Rising Dose Study of BI 655088 Administered Intravenously in Healthy Male Volunteers
Investigation of safety and tolerability of BI 655088 following intravenous infusion of single rising doses and exploration of the pharmacokinetics and pharmacodynamics of BI 655088 after single dosing
- Trial name
- NCT02696616
- Testing
- BI 655088
- Where
- Belgium
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Moderate-to-severe Inflammatory Bowel Disease
A Study to Evaluate the Safety of SHR-7590 in Chinese Healthy Participants and in Patients With Moderate-to-severe Inflammatory Bowel Disease
This Phase I first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-7590 via subcutaneous or intravenous administration in Chinese healthy participants and patients with…
- Trial name
- NCT07758101
- Testing
- SHR-7590
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Hypoplasminogenemia, Congenital Plasminogen Deficiency
A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia
This is a Phase 2/3 pivotal study to evaluate pharmacokinetics (PK), efficacy, and safety of Prometic Plasminogen (Human) Intravenous Lyophilized Solution, the investigational medicinal product (IMP), in pediatric and adult…
- Trial name
- NCT02690714
- Testing
- Plasminogen (Human) intravenous
- Where
- 2 sites in United States, Norway
- Volunteers
- 15 people
- Sponsor
- Prometic Biotherapeutics, Inc.
Healthy, Postmenopausal
AZD1981 Bioavailability Study of Intravenous (IV) and Oral Formulations
The primary objective is to investigate the pharmacokinetics of AZD1981 given in different formulations and to measure renal clearance
- Conditions
- Healthy, Postmenopausal, Surgically Sterile Women
- Trial name
- NCT00918398
- Testing
- AZD1981
- Where
- Sweden
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hemorrhage
This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding
The primary objective is to demonstrate reversal of the anticoagulant effect of dabigatran in patients treated with dabigatran etexilate who have uncontrolled or life-threatening bleeding requiring urgent intervention, and in…
- Trial name
- NCT03343704
- Testing
- Idarucizumab
- Where
- 13 sites in China
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor Cancer, Lymphoma
Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas
SB-485232 will be administered as five daily intravenous (IV) infusions repeated every 28 days in adult subjects with advanced solid tumors or lymphomas.
- Trial name
- NCT00085904
- Testing
- SB-485232
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Osteosarcoma, Soft Tissue Sarcoma (STS)
ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on bone and soft tissue sarcoma.
- Trial name
- NCT06699576
- Testing
- HS-20093, Anlotinib, Epirubicin
- Volunteers
- 448 people
- Sponsor
- Hansoh BioMedical R&D Company
Stroke
First in Human Study to Compare Safety Between Intravenous Bolus Versus Infusion of ApTOLL
The main objective of the study is to assess the tolerability and safety of ApTOLL administration when comparing intravenous infusion vs. bolus intravenous injection, in healthy volunteers.
- Trial name
- APTABOLUS (NCT05569720)
- Testing
- ApTOLL
- Where
- Spain
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- aptaTargets S.L.
Aneurysmal Subarachnoid Hemorrhage
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
The purpose of the study is to measure how effective and safe three different doses of the drug clazosentan are in preventing vasospasm after subarachnoid hemorrhage.
- Trial name
- CONSCIOUS-1 (NCT00111085)
- Testing
- Clazosentan 1 mg/h, Clazosentan 5 mg/h, Clazosentan 15 mg/h
- Where
- 16 sites in United States, Canada
- Volunteers
- 413 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Heart Failure
Phase I Interaction Study of Istaroxime and Digoxin in Subjects With Stable Heart Failure
This study explores a potential drug-drug interaction between istaroxime and digoxin in patients with stable CHF on chronic oral digoxin treatment.
- Trial name
- NCT00869115
- Testing
- Istaroxime
- Sponsor
- Debiopharm International SA
Moderate to Severe Chronic Plaque Psoriasis
Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients
This is a Phase IIa, randomised, double-blind, placebo-controlled, multiple dose, multi-center study of AbGn-168H in subjects with moderate to severe chronic plaque psoriasis.The objectives of this study is to investigate…
- Trial name
- AbGn-168H (NCT01855880)
- Testing
- AbGn-168H
- Where
- 15 sites in United States
- Volunteers
- 54 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological…
- Conditions
- Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
- Trial name
- NCT05086315
- Testing
- SAR443579
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 101 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
Study of an Anti-TLR4 mAb in Rheumatoid Arthritis
This is a Phase 2, PoC, randomized, placebo-controlled, double blind, international multicentre study to explore the effect of a new antibody to treat patients with Rheumatoid Arthritis
- Trial name
- NCT03241108
- Testing
- NI-0101
- Where
- 19 sites in Bosnia and Herzegovina, Bulgaria and 5 more
- Volunteers
- 90 people
- Sponsor
- Light Chain Bioscience - Novimmune SA
Sickle Cell Disease
Clinical Study of BRL-101 in Severe SCD
This is a single center, non-randomized, open label, single-dose study in subjects with Sickle Cell Disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem…
- Trial name
- NCT06300723
- Testing
- BRL-101
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Bioray Laboratories
Rheumatoid Arthritis
Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis
This is a randomized double-blind comparative parallel group study of the efficacy and safety of tocilizumab biosimilar Complarate® and Actemra® in the treatment of patients with rheumatoid arthritis with moderate to high disease…
- Trial name
- NCT06475508
- Testing
- Complarate®, Actemra®
- Where
- 28 sites in Russia
- Volunteers
- 465 people
- Sponsor
- AO GENERIUM